Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-10-16
1995-02-07
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549366, C07D31920, A61K 31335
Patent
active
053876040
ABSTRACT:
The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.
REFERENCES:
patent: 2725386 (1955-11-01), Bovet et al.
patent: 4614807 (1986-09-01), Flaugh
Derwent Abstract No. 88-16312224.
Derwent Abstract No. 86-190385/30.
Marinus O. den Boer, et al, Br. J. Pharmacol (1991), 102, pp. 323-330, Role of 5HT.sub.1 -like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.
Saxena, et al, TiPS, May 1989, vol. 10, pp. 200-204; 5HT.sub.1 -like receptor agonists and the pathophysiology of migraine.
Hamel et al., Br. J. Pharmacol, (1991), 102, pp. 227-233; Contractile 5HT.sub.1 receptors in human isolated pial arterioles: correlation with 5-HT.sub.1D binding sites.
Edward E. Schwiezer, et al.; Psychopharmacology Bulleting, vol. 22, No. 1, 1986, pp. 183-185; Open Trial of Buspirone in the Treatment of Major Depressive Disorder.
European Journal of Pharmacology, 180 (1990) pp. 339-349, Dreteler, et al.; Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flexinoxan with that of 8-OH-DPAT in the rat.
European Journal of Pharmacology, 182 (1990) 63-72, Connor, et al.; Cardiovascular effects of 5HT.sub.1a receptor agonists injected into the dorsal raphe nucleus of conscious rats.
Clinical Neuropharmacology, vol. 14, No. 3, pp. 245-250, Julio Pascual, et al.; An open trial of Buspirone in Migraine Prophylaxis. Preliminary Report. (1990).
European Journal of Pharmacology, 163, (1989) 133-136, Peroutka, et al; Sumatriptan (GR 43175) interacts selectively with 5-HT.sub.1B and 5-HT.sub.1D binding sites.
Bernotas Ronald C.
Dudley Mark W.
McDonald Ian A.
Sprouse Jeffrey S.
Dixon J. Michael
Merrell Dow Pharmaceuticals Inc.
Springer David B.
LandOfFree
1,4 benzodioxin derivatives and their use as serotonin 5HT.sub.1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4 benzodioxin derivatives and their use as serotonin 5HT.sub.1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4 benzodioxin derivatives and their use as serotonin 5HT.sub.1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1110655